dbco-peg4-ahx-dm1

DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate that combines the microtubulin inhibitor DM1 (mertansine), which is an antibody-conjugatable maytansinoid designed to reduce systemic toxicity and improve tumor-specific delivery, with the linker DBCO-PEG4-Ahx, for the development of antibody drug conjugates (ADCs).

N-Boc-4-pentyne-1-amine is an alkyl chain-based PROTAC linker compound utilized in the synthesis of PROTAC MG-277[1].

DBCO-(PEG)3-VC-PAB-MMAE is a chemical compound where monomethyl auristatin E (MMAE), a potent tubulin inhibitor acting as a toxin payload in antibody-drug conjugates, is conjugated to a DBCO-(PEG)3-vc-PAB linker.

Tetraethyl butane- 1, 4- diylbis(phosphoramid ate) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1].

N-(m-PEG4)-N'-(4-Hydroxycyclohexyl-1-amido-PEG4)-Cy5 is a polyethylene glycol (PEG)-based linker compound primarily utilized in the synthesis of proteolysis-targeting chimeras (PROTACs)[1].

DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for the development of antibody-drug conjugates (ADCs). This conjugation aims to mitigate the systemic toxicity associated with maytansine while improving tumor-specific delivery, leveraging DM1’s capabilities as an antibody-conjugatable maytansinoid.